

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025  
Date of first issue: 21.09.2020

---

### SECTION 1. IDENTIFICATION

Product identifier : Milbemycin Oxime / Lufenuron Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530  
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification in accordance with ABNT NBR 14725 Standard

Skin sensitization : Category 1

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 1 (Central nervous system, Lungs, Liver, Stomach)  
repeated exposure (Oral)

Specific target organ toxicity - : Category 2 (Central nervous system)  
repeated exposure

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

#### GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H317 May cause an allergic skin reaction.

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1	Revision Date: 09.05.2025	SDS Number: 6365191-00011	Date of last issue: 14.04.2025 Date of first issue: 21.09.2020
----------------	------------------------------	------------------------------	---

H360D May damage the unborn child.  
H372 Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure if swallowed.  
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

### Precautionary Statements

#### : Prevention:

P201 Obtain special instructions before use.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### : Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P391 Collect spillage.

#### : Storage:

P405 Store locked up.

### Other hazards which do not result in classification

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Lufenuron (ISO)	103055-07-8	Acute Tox. (Oral), 5 Acute Tox. (Dermal), 5 Skin Sens., 1 Repr., 1B STOT RE, (Oral)(Central nervous system, Lungs, Liver, Stomach) , 1 Aquatic Acute, 1 Aquatic Chronic, 1	>= 30 - < 50
Cellulose	9004-34-6		>= 10 - < 20
Starch	9005-25-8		>= 5 - < 10
Milbemycin Oxime	129496-10-2	Acute Tox. (Oral), 4 Acute Tox. (Inhalation), 4	>= 1 - < 2,5

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025 Date of first issue: 21.09.2020

		Acute Tox. (Dermal), 5 STOT RE, (Central nervous system) , 1 Aquatic Acute, 1 Aquatic Chronic, 1	
--	--	---	--

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.

In case of eye contact : Thoroughly clean shoes before reuse.  
Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.  
May damage the unborn child.  
Causes damage to organs through prolonged or repeated exposure if swallowed.  
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1	Revision Date: 09.05.2025	SDS Number: 6365191-00011	Date of last issue: 14.04.2025 Date of first issue: 21.09.2020
----------------	------------------------------	------------------------------	---

Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## SECTION 7. HANDLING AND STORAGE

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing. Avoid breathing dust, fume, gas, mist, vapors or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1	Revision Date: 09.05.2025	SDS Number: 6365191-00011	Date of last issue: 14.04.2025 Date of first issue: 21.09.2020
----------------	------------------------------	------------------------------	---

When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage	: Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Lufenuron (ISO)	103055-07-8	TWA	200 µg/m <sup>3</sup> (OEB 2)	Internal
Further information: DSEN				
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	ACGIH
Milbemycin Oxime	129496-10-2	TWA	0.1 mg/m <sup>3</sup> (OEB2)	Internal

Engineering measures	: Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
----------------------	--

### Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025  
Date of first issue: 21.09.2020

---

potential for direct contact to the face with dusts, mists, or aerosols.  
Skin and body protection : Work uniform or laboratory coat.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : solid  
Color : brown  
Odor : odorless  
Odor Threshold : No data available  
pH : No data available  
Melting point/freezing point : No data available  
Initial boiling point and boiling range : No data available  
Flash point : Not applicable  
Evaporation rate : Not applicable  
Flammability (solid, gas) : No data available  
Flammability (liquids) : Not applicable  
Upper explosion limit / Upper flammability limit : No data available  
Lower explosion limit / Lower flammability limit : No data available  
Vapor pressure : Not applicable  
Relative vapor density : Not applicable  
Relative density : No data available  
Density : No data available  
Solubility(ies)  
Water solubility : soluble  
Partition coefficient: n-octanol/water : Not applicable  
Autoignition temperature : No data available  
Decomposition temperature : No data available  
Viscosity  
Viscosity, kinematic : Not applicable

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025 Date of first issue: 21.09.2020

Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	No data available

## SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

## SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Skin contact Ingestion Eye contact
--	---	--

### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: > 10 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method

#### Components:

##### **Lufenuron (ISO):**

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg LD50 (Mouse): > 2.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): 2.350 mg/m <sup>3</sup> Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg

## SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025  
4.1 09.05.2025 6365191-00011 Date of first issue: 21.09.2020

## Cellulose:

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5,8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg

## Starch:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

## Milbemycin Oxime:

Acute oral toxicity	: LD50 (Rat): 532 - 863 mg/kg
	LD50 (Mouse): 722 - 946 mg/kg
Acute inhalation toxicity	: LC50 (Rat): 1.200 mg/m <sup>3</sup> Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rat): > 2.000 mg/kg

### Skin corrosion/irritation

Not classified based on available information.

## Components:

## **Lufenuron (ISO):**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

## **Milbemycin Oxime:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

## **Serious eye damage/eye irritation**

Not classified based on available information.

## **Components:**

## Lufenuron (ISO):

Species : Rabbit  
Result : No eye irritation  
Method : Draize Test

## SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025  
4.1 09.05.2025 6365191-00011 Date of first issue: 21.09.2020

## Starch:

Species : Rabbit  
Result : No eye irritation

## Milbemycin Oxime:

Species : Rabbit  
Result : No eye irritation

### **Respiratory or skin sensitization**

## Skin sensitization

May cause an allergic skin

## Respiratory sensitization

Not classified b

## Components.

<b>Lufenuron (ISO):</b>	
Test Type	: Maximization Test
Species	: Guinea pig
Assessment	: May cause sensitization by skin contact.
Result	: Sensitizer

## Starch

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

## Milbemycin Oxime:

Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

## Germ cell mutagenicity

Not classified based on available information

## Components:

## **Lufenuron (ISO):**

Genotoxicity in vitro : Test Type: Ames test  
Result: negative

Test Type: Mouse Lymphoma  
Test system: Chinese hamster cells  
Result: negative

Test Type: Cytogenetic assay  
Test system: Chinese hamster ovary cells  
Result: negative

**Milbemycin Oxime / Lufenuron Formulation**

Version 4.1	Revision Date: 09.05.2025	SDS Number: 6365191-00011	Date of last issue: 14.04.2025 Date of first issue: 21.09.2020
----------------	------------------------------	------------------------------	---

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: rat hepatocytes  
Result: negative

Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Result: negative

Test Type: Unscheduled DNA synthesis test (UDS) in testicular cells  
Species: Rat  
Result: negative

Germ cell mutagenicity - Assessment

: Weight of evidence does not support classification as a germ cell mutagen.

**Cellulose:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Starch:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Milbemycin Oxime:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Milbemycin Oxime / Lufenuron Formulation**

Version      Revision Date:      SDS Number:      Date of last issue: 14.04.2025  
4.1            09.05.2025            6365191-00011      Date of first issue: 21.09.2020

---

**Components:****Lufenuron (ISO):**

Species : Rat  
Application Route : Ingestion  
Exposure time : 18 month(s)  
Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

**Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Reproductive toxicity**

May damage the unborn child.

**Components:****Lufenuron (ISO):**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity Parent: NOAEL: 8,3 mg/kg wet weight  
Early Embryonic Development: NOAEL: 20,9 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 500 mg/kg body weight  
Developmental Toxicity: NOAEL: 1.000 mg/kg body weight  
Symptoms: No adverse effects.  
Remarks: No significant adverse effects were reported

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
General Toxicity Maternal: NOAEL: 20,9 mg/kg body weight  
Embryo-fetal toxicity.: 8,3 mg/kg body weight  
Result: Fetal abnormalities.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025 Date of first issue: 21.09.2020

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### **Milbemycin Oxime:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Dog  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: negative

Test Type: Embryo-fetal development  
Species: Dog  
Application Route: Ingestion  
Result: negative

### **STOT-single exposure**

Not classified based on available information.

### **Components:**

#### **Lufenuron (ISO):**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

### **STOT-repeated exposure**

Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure if swallowed.

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

### **Components:**

#### **Lufenuron (ISO):**

Routes of exposure : Oral  
Target Organs : Central nervous system, Lungs, Liver, Stomach  
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

### **Milbemycin Oxime:**

Routes of exposure : Ingestion  
Target Organs : Central nervous system

**Milbemycin Oxime / Lufenuron Formulation**

Version      Revision Date:      SDS Number:      Date of last issue: 14.04.2025  
4.1            09.05.2025            6365191-00011      Date of first issue: 21.09.2020

---

Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity****Components:****Lufenuron (ISO):**

Species	:	Rat
NOAEL	:	5,34 mg/kg
Application Route	:	oral (feed)
Exposure time	:	4 Months
Target Organs	:	Central nervous system, digestive system
Symptoms	:	central nervous system effects
Species	:	Rat
NOAEL	:	1,93 mg/kg
Application Route	:	oral (feed)
Exposure time	:	2 y
Symptoms	:	central nervous system effects, Convulsions
Species	:	Mouse
NOAEL	:	2,12 mg/kg
Application Route	:	oral (feed)
Exposure time	:	18 Months
Target Organs	:	Central nervous system, Liver, Prostate
Symptoms	:	central nervous system effects, Convulsions
Species	:	Dog
NOAEL	:	7,02 mg/kg
Application Route	:	oral (feed)
Exposure time	:	1 y
Target Organs	:	Central nervous system, Liver, Lungs
Symptoms	:	Convulsions, Fatality, Irregularities

**Cellulose:**

Species	:	Rat
NOAEL	:	>= 9.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

**Starch:**

Species	:	Rat
NOAEL	:	>= 2.000 mg/kg
Application Route	:	Skin contact
Exposure time	:	28 Days
Method	:	OECD Test Guideline 410

**Milbemycin Oxime:**

Species	:	Rat
NOAEL	:	3 mg/kg
LOAEL	:	15 mg/kg

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025 Date of first issue: 21.09.2020

---

Application Route	:	Ingestion
Exposure time	:	90 Days
Symptoms	:	Liver disorders, Blood disorders
Species	:	Dog
LOAEL	:	8,6 mg/kg
Application Route	:	Ingestion
Exposure time	:	3 Days
Symptoms	:	Tremors

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### **Lufenuron (ISO):**

General Information : Remarks: May be harmful if swallowed.  
May cause neurotoxic effects.

##### **Milbemycin Oxime:**

Ingestion : Symptoms: Salivation, Convulsions, Diarrhea, Weakness,  
Vomiting, Tremors, Coma  
Remarks: Based on Animal Evidence

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### **Lufenuron (ISO):**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 73.100 µg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): > 29.000 µg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 370 µg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0,042 µg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035

EC50 (Daphnia magna (Water flea)): 0,41 µg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Raphidocelis subcapitata (freshwater green alga)): 209 µg/l

## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025 Date of first issue: 21.09.2020

Exposure time: 72 h  
Method: OECD Test Guideline 201

EC50 (Scenedesmus subspicatus): 17 µg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10.000  
Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 80 µg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

NOEC (Oncorhynchus mykiss (rainbow trout)): 20 µg/l  
Exposure time: 359 d  
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 8,38 µg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

NOEC (Daphnia magna (Water flea)): 90 µg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

NOEC (Chironomus riparius (harlequin fly)): 2 µg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 10

### Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

### Milbemycin Oxime:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0,16 µg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,03 µg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50: > 87 µg/l  
Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 10.000

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,01 µg/l

M-Factor (Chronic aquatic toxicity) : 10.000

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025 Date of first issue: 21.09.2020

---

### Persistence and degradability

#### Components:

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

### Bioaccumulative potential

#### Components:

##### **Lufenuron (ISO):**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 28  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 5,12

##### **Milbemycin Oxime:**

Bioaccumulation : Bioconcentration factor (BCF): 440

Partition coefficient: n-octanol/water : log Pow: 7

### Mobility in soil

#### Components:

##### **Lufenuron (ISO):**

Distribution among environmental compartments : log Koc: 5,38  
Method: OECD Test Guideline 106

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### **UNRTDG**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Milbemycin Oxime, Lufenuron (ISO))

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025  
Date of first issue: 21.09.2020

---

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Milbemycin Oxime, Lufenuron (ISO))  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,  
N.O.S.  
(Milbemycin Oxime, Lufenuron (ISO))  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### ANTT

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,  
N.O.S.  
(Milbemycin Oxime, Lufenuron (ISO))  
Class : 9  
Packing group : III  
Labels : 9  
Hazard Identification Number : 90

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - : Not applicable  
(LINACH)

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365191-00011 Date of last issue: 14.04.2025 Date of first issue: 21.09.2020

---

Brazil. List of chemicals controlled by the Federal Police : Not applicable

### The ingredients of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

## SECTION 16. OTHER INFORMATION

Revision Date : 09.05.2025  
Date format : dd.mm.yyyy

### Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Sub-

# SAFETY DATA SHEET



## Milbemycin Oxime / Lufenuron Formulation

Version  
4.1

Revision Date:  
09.05.2025

SDS Number:  
6365191-00011

Date of last issue: 14.04.2025  
Date of first issue: 21.09.2020

stances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8